NEU — Neuren Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- AU$2.41bn
- AU$2.18bn
- AU$237.63m
- 91
- 57
- 82
- 87
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.884 | 0.864 | 3.24 | 15.8 | 238 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 11.6 | 9.53 | 11.4 | 16.1 | 32.7 |
Operating Profit | -10.7 | -8.66 | -8.19 | -0.341 | 205 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -10.8 | -9.19 | -7.79 | 0.184 | 205 |
Provision for Income Taxes | |||||
Net Income After Taxes | -10.8 | -9.19 | -7.79 | 0.184 | 157 |
Net Income Before Extraordinary Items | |||||
Net Income | -10.8 | -9.19 | -7.79 | 0.184 | 157 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -10.8 | -9.19 | -7.79 | 0.184 | 157 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.108 | -0.086 | -0.066 | 0.001 | 1.24 |